Unity Biotechnology, Inc. Quarterly Operating Income (Loss) in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Unity Biotechnology, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2017 to Q3 2024.
  • Unity Biotechnology, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$6.6M, a 54.7% increase year-over-year.
  • Unity Biotechnology, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$28.9M, a 42.3% increase year-over-year.
  • Unity Biotechnology, Inc. annual Operating Income (Loss) for 2023 was -$44.7M, a 22.4% increase from 2022.
  • Unity Biotechnology, Inc. annual Operating Income (Loss) for 2022 was -$57.6M, a 1.6% decline from 2021.
  • Unity Biotechnology, Inc. annual Operating Income (Loss) for 2021 was -$56.7M, a 39.7% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$28.9M -$6.6M +$7.98M +54.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-04
Q2 2024 -$36.8M -$6.98M +$4.87M +41.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$41.7M -$7.6M +$2.96M +28% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$44.7M -$7.68M +$5.36M +41.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-15
Q3 2023 -$50M -$14.6M -$573K -4.09% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-04
Q2 2023 -$49.5M -$11.8M +$410K +3.35% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$49.9M -$10.6M +$7.71M +42.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$57.6M -$13M -$3.14M -31.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-15
Q3 2022 -$54.4M -$14M +$820K +5.53% Jul 1, 2022 Sep 30, 2022 10-K 2024-04-15
Q2 2022 -$55.3M -$12.3M +$4.74M +27.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$60M -$18.3M -$3.32M -22.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$56.7M -$9.9M +$8.89M +47.3% Oct 1, 2021 Dec 31, 2021 10-K 2024-04-15
Q3 2021 -$65.6M -$14.8M +$9.81M +39.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$75.4M -$17M +$6.35M +27.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$81.7M -$14.9M +$12.2M +45% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$93.9M -$18.8M +$4.31M +18.7% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-23
Q3 2020 -$98.2M -$24.6M -$2.29M -10.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$95.9M -$23.3M +$1.12M +4.58% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 -$97.1M -$27.2M -$7.42M -37.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q4 2019 -$89.7M -$23.1M -$282K -1.24% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-23
Q3 2019 -$89.4M -$22.4M -$2.98M -15.4% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-23
Q2 2019 -$86.4M -$24.5M -$3.67M -17.7% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-23
Q1 2019 -$82.7M -$19.7M -$3.26M -19.7% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-23
Q4 2018 -$79.5M -$22.8M -$10M -78.4% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-11
Q3 2018 -$69.4M -$19.4M -$7.29M -60.4% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-11
Q2 2018 -$62.2M -$20.8M -$9.1M -77.8% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-11
Q1 2018 -$53.1M -$16.5M -$7.44M -82.3% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-11
Q4 2017 -$45.6M -$12.8M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-06
Q3 2017 -$12.1M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-06
Q2 2017 -$11.7M Apr 1, 2017 Jun 30, 2017 10-K 2019-03-06
Q1 2017 -$9.04M Jan 1, 2017 Mar 31, 2017 10-K 2019-03-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.